

ImmuPharma

49.5p

Preliminary Results and a promising start to this year

■ ImmuPharma announces its Preliminary Results as well as reiterating a number of positive developments for the start of this year. The most significant that it has entered into a Collaboration Agreement with Simbec-Orion Group Limited, a well-regarded, full service, international Clinical Research Organisation (CRO) for the further development of Lupuzor™. Simbec-Orion is to invest a significant proportion of its fee in ImmuPharma shares, at a fixed price of 150p. This provides a strong endorsement for both the validation and prospective valuation of the Lupuzor™ asset. Lupuzor™ was granted an updated Special Protocol Assessment (SPA), which allows a reduced number of patients in the trial, thus reducing its time and cost. The agreement also leaves options open for the company's future strategy with the possibility of retaining the rights to Lupuzor™ to commercialisation. The Phase I/IIa trial for ImmuPharma's cancer programme has been completed with further applications identified. The company has a strong cash position of £5.4m and shareholder backing, which was demonstrated by the successful £3.4m fundraising completed in October. The £50m equity finance facility with Darwin Strategic also provides further financial flexibility to the group.

■ Final results reveal strong cash position

In common with other drug development companies the group remains substantially pre-revenue, importantly keeping cash burn well controlled. The results show losses for the year to 31 December were reduced to £2.9m (2013: £3.7m), loss per share 3.43p (2013: -4.52p) and cash came in ahead of expectations at £5.4m (2013: £5.4m).

■ Development of Lupuzor™ could provide significant upside for investors

Lupuzor™ is entering pivotal Phase III trials, the last step before filing for FDA approval. If successful, the company has many strategic options including pursuing further corporate deals and/or taking the drug directly to market. The drug has a multi-billion dollar sales potential in a market of un-met needs, which should generate significant shareholder value.

■ Pipeline showing further promise

The Nucant cancer programme has completed a Phase I/IIa clinical trial using the next generation 'polyplexed Nucant' drug formulation. Further news on the programme is expected in due course. New patents for an 'optically pure' version of the Nucant family have been awarded providing longer exclusivity and extending the Nucant program to other indications beyond cancer. In collaboration with the University of Bordeaux and the CNRS, ImmuPharma is seeking to identify and patent novel peptide drugs. This has added a breakthrough technology called 'Urelix' to the company's portfolio and this has been awarded a €400,000 grant. These assets all offer exciting future potential for the group.



TDIM	IMM
Market Cap (£m)	43.9
Net Cash (£m)	4.2m
Free float (%)	63.0
Avg daily volume (3m)	65k
Broker	Panmure Gordon
Listing	AIM

Liz Burrows
research@broker-profile.com
+44 20 7448 3244

	Sales (£m)	PBT (£m)	EPS (p)	Net Cash (£m)	P/E (x)	EV/EBITDA (x)	Yield (%)
FY14a	0.18	(3.34)	(3.43)	5.42	0.0	0.0	0.0
FY15e	0.0	(4.10)	(4.06)	1.77	0.0	0.0	0.0
FY16e	0.0	(4.10)	(4.06)	(1.88)	0.0	0.0	0.0

This document provides information on ImmuPharma plc - it is not a solicitation of an offer to buy or sell securities. See the disclaimer on the back page.

New Non-Executive Director Appointment

We also note the appointment of Dr Stéphane Méry to the Board as a non-executive director, a French national whose wide industry and investment background will be invaluable as Lupuzor™ moves forward in its pivotal Phase III trial.

Interim Board Change

Subsequent to the final results announcement the company has announced that the Executive Chairman, Richard Warr, has taken leave of absence due to recent ill health. Dr Franco Di Muzio, Senior Non-Executive Director will take on the role of Chairman on an interim basis. Dr Franco Di Muzio has 40 years' experience in pharmaceutical and other industries and has been the Senior Non-Executive Director of ImmuPharma since its formation giving him in-depth knowledge of the company.

Annual Report and Accounts and AGM

The company has also announced that the Annual Report and Accounts has been posted out to shareholders and that the AGM will be held on Friday 29 May.

This document is a marketing communication which is designed to educate and inform professional investors about the subject company. The subject company pays Broker Profile Research a fixed annual fee to cover the costs of research production and distribution, and the research has not been prepared in accordance with regulatory requirements designed to promote the independence of investment research. Broker Profile Research does not make recommendations. Any comments in this report regarding the valuation of a financial security are based on comparisons with similar securities; they are not forecasts of a likely share price. This document is not an offer to buy or sell, or a solicitation of an offer to buy or sell, the securities mentioned.

Broker Profile does not buy or sell shares, nor does it conduct corporate finance transactions, nor does it undertake investment business either in the UK or elsewhere. Broker Profile Research is not regulated by the Financial Conduct Authority (FCA). Neither Broker Profile Research nor the analyst responsible for this research owns shares or other securities issued by the company analysed in this research note, nor do they have a position in any derivative contract based on those securities.

This research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended for retail investors. Any such individual who comes into possession of this research should consult an authorised professional adviser.

The information contained in this document has been compiled from sources believed to be reliable, but no guarantee whatsoever is given that the information is complete or accurate, or that it is fit for a particular purpose. This document was issued by Broker Profile Research without legal responsibility, and is subject to change or withdrawal without notice. By reading this document, you confirm that you have read and understand the above, and that you shall not hold Broker Profile Research or any of its members and connected companies liable for any loss that you may sustain should you decide to buy or sell any of the mentioned securities."

Broker Profile Research
Augustine House
6A Austin Friars
London EC2N 2HA
www.brokerprofileresearch.com



BROKER
PROFILE
RESEARCH